ADBE vs DHR: Which Is the Better Buy?
Side-by-side comparison of Adobe Inc. and Danaher Corporation — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-05-04.
Adobe Inc. · Technology
$248.16
+163.1% upside to fair value
High Conviction
Grade B
VS
Danaher Corporation · Healthcare
$174.04
+13.2% upside to fair value
Grade B
QuantHub Verdict
ADBE has more upside to fair value
(+163.1%).
ADBE trades at a lower forward P/E
(14.1x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
ADBE |
DHR |
| Current Price |
$248.16 |
$174.04 |
| Fair Value Estimate |
$653.00 |
$197.01 |
| Upside to Fair Value |
+163.1%
|
+13.2%
|
| Market Cap |
$101.2B |
$123.2B |
| Forward P/E |
14.1x
|
33.4x
|
| EV / EBITDA |
—
|
20.3x
|
| Price / Sales |
4.1x
|
5.0x
|
| Price / FCF |
9.8x
|
23.3x
|
| Revenue Growth YoY |
+3.3%
|
+3.7%
|
| Gross Margin |
89.1%
|
60.7%
|
| Operating Margin |
36.6%
|
21.0%
|
| Return on Equity |
62.3%
|
7.1%
|
| Dividend Yield |
— |
0% |
| FCF Yield |
10.2%
|
4.3%
|
| Analyst Consensus |
Hold
|
Strong Buy
|
Investment Thesis
Adobe Inc. develops industry-leading creative software, digital experience platforms, and publishing tools, powering digital content creation and marketing for professionals worldwide. The business excels with high gross margins above 89%, a sticky subscription model driving recurring revenue over $17B ARR, and dominant moats in digital media, though it faces intensifying AI competition and slowi…
Danaher Corporation is a diversified healthcare company focused on medical diagnostics, life sciences, and biotechnology, generating approximately $24 billion in revenue with a strong recurring revenue base of over 81%. The company benefits from a high gross margin of 60.7% and solid operating margin of 21%, supported by a seasoned management team with a proven capital allocation track record inc…
Accumulation Zones
| Metric |
ADBE |
DHR |
| Zone Low |
$490.00 |
$147.76 |
| Zone High |
$555.00 |
$167.46 |
| In Buy Zone? |
Yes
|
No
|